Last reviewed · How we verify
Typhoid Vi polysaccharide — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Typhoid Vi polysaccharide (Typhoid Vi polysaccharide) — Sanofi Pasteur, a Sanofi Company. Typhoid Vi polysaccharide vaccine induces an immune response against Salmonella Typhi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Typhoid Vi polysaccharide TARGET | Typhoid Vi polysaccharide | Sanofi Pasteur, a Sanofi Company | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Typhoid Vi polysaccharide CI watch — RSS
- Typhoid Vi polysaccharide CI watch — Atom
- Typhoid Vi polysaccharide CI watch — JSON
- Typhoid Vi polysaccharide alone — RSS
Cite this brief
Drug Landscape (2026). Typhoid Vi polysaccharide — Competitive Intelligence Brief. https://druglandscape.com/ci/typhoid-vi-polysaccharide. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing